Thomas Elmer Witzig, MD

  • 41689 Citations
  • 110 Scopus h-Index
1985 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Thomas Elmer Witzig is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 54 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Signal transduction inhibitor therapy for Lymphoma

Witzig, T. E.

9/20/077/31/14

Project: Research project

PI3K Pathway Inhibitors for Mantle Cell Lymphoma

Witzig, T. E.

8/18/057/31/09

Project: Research project

Radioimmunotherapy for Lymphoma

Witzig, T. E.

4/1/013/31/06

Project: Research project

  • Research Output

    Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

    Hampel, P. J., Call, T. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., Fonder, A. L., Schwager, S. M., Rabe, K. G., Van Dyke, D. L., Braggio, E., Slager, S. L., Kay, N. E. & Parikh, S. A., Mar 1 2020, In : American journal of hematology. 95, 3, p. E57-E60

    Research output: Contribution to journalLetter

    Open Access

    Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma

    St-Pierre, F., Broski, S. M., LaPlant, B. R., Maurer, M. J., Ristow, K., Thanarajasingam, G., Macon, W. R., Habermann, T. M. & Witzig, T. E., Jan 1 2020, (Accepted/In press) In : Oncologist.

    Research output: Contribution to journalArticle

    Open Access
  • Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma

    Gile, J., Ruan, G., Abeykoon, J., McMahon, M. M., Macon, W. R. & Witzig, T. E., Jan 1 2020, (Accepted/In press) In : Leukemia and Lymphoma.

    Research output: Contribution to journalLetter

    Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia

    Zanwar, S., Abeykoon, J. P., Durot, E., King, R., Perez Burbano, G. E., Kumar, S., Gertz, M. A., Quinquenel, A., Delmer, A., Gonsalves, W., Cornillet-Lefebvre, P., He, R., Warsame, R., Buadi, F. K., Novak, A. J., Greipp, P. T., Inwards, D., Habermann, T. M., Micallef, I., Go, R. & 19 others, Muchtar, E., Kourelis, T., Dispenzieri, A., Lacy, M. Q., Dingli, D., Nowakowski, G., Thompson, C. A., Johnston, P., Thanarajasingam, G., Bennani, N. N., Witzig, T. E., Villasboas, J., Leung, N., Lin, Y., Kyle, R. A., Rajkumar, S. V., Ansell, S. M., Le-Rademacher, J. G. & Kapoor, P., Mar 1 2020, In : American journal of hematology. 95, 3, p. 274-281 8 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

    Thanarajasingam, G., Leonard, J. P., Witzig, T. E., Habermann, T. M., Blum, K. A., Bartlett, N. L., Flowers, C. R., Pitcher, B. N., Jung, S. H., Atherton, P. J., Tan, A., Novotny, P. J. & Dueck, A. C., Jun 2020, In : The Lancet Haematology. 7, 6, p. e490-e497

    Research output: Contribution to journalReview article